🟢 Novo Nordisk is trading 3.17% up in after-hours trading as UK Foundayo launch intensifies oral obesity-drug competition

Novo Nordisk is trading 3.17% up at $48.68 after-hours, as Eli Lilly’s Foundayo became available in the UK, intensifying oral obesity-drug competition with Novo Nordisk’s Wegovy pill.

• Shares closed at $47.19 on August 26, 2026, after declining 3.02% during the regular session.
• The S&P 500 gained 0.54%, providing a modest supportive backdrop.
• No new company-specific after-hours catalyst was verified.